Wagner Bowman Management Corp Has $1,122,000 Stake in Bristol-Myers Squibb Co. (BMY)
Wagner Bowman Management Corp reduced its position in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 0.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,264 shares of the biopharmaceutical company’s stock after selling 41 shares during the period. Wagner Bowman Management Corp’s holdings in Bristol-Myers Squibb were worth $1,122,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new position in Bristol-Myers Squibb during the second quarter worth approximately $154,732,000. Canada Pension Plan Investment Board increased its position in Bristol-Myers Squibb by 628.9% in the first quarter. Canada Pension Plan Investment Board now owns 1,323,821 shares of the biopharmaceutical company’s stock worth $84,566,000 after buying an additional 1,142,200 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new position in Bristol-Myers Squibb during the first quarter worth approximately $69,778,000. TIAA CREF Investment Management LLC increased its position in Bristol-Myers Squibb by 9.8% in the first quarter. TIAA CREF Investment Management LLC now owns 10,372,071 shares of the biopharmaceutical company’s stock worth $662,568,000 after buying an additional 921,866 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its position in Bristol-Myers Squibb by 1.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 44,742,184 shares of the biopharmaceutical company’s stock worth $2,858,131,000 after buying an additional 844,233 shares during the last quarter. Institutional investors and hedge funds own 72.88% of the company’s stock.
Bristol-Myers Squibb Co. (NYSE:BMY) traded down 10.14% during midday trading on Monday, hitting $49.81. The stock had a trading volume of 65,241,277 shares. The firm has a 50 day moving average price of $56.41 and a 200 day moving average price of $66.79. The stock has a market cap of $83.23 billion, a PE ratio of 29.13 and a beta of 0.75. Bristol-Myers Squibb Co. has a one year low of $49.54 and a one year high of $77.12.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The business earned $4.90 billion during the quarter, compared to the consensus estimate of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The business’s revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.53 earnings per share. Equities analysts expect that Bristol-Myers Squibb Co. will post $2.63 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be given a $0.38 dividend. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a yield of 3.05%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 87.36%.
BMY has been the subject of a number of research analyst reports. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Wednesday, July 13th. Berenberg Bank reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, July 12th. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, July 6th. Citigroup Inc. decreased their target price on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, August 3rd. Finally, Leerink Swann reissued a “buy” rating and issued a $85.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, July 29th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $69.31.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $56.87, for a total value of $1,228,392.00. Following the completion of the sale, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.24% of the stock is owned by company insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.